Efficacy and safety of zidovudine, lamivudine, and tenofovir combination in antiretroviral naive, HIV-1 infected patients

被引：0
|
作者：
Rey, D [1 ]
Krebs, M [1 ]
Partisani, M [1 ]
Hess-Kempf, G [1 ]
Cheneau, C [1 ]
Priester, M [1 ]
Bernard-Henry, C [1 ]
De Mautort, E [1 ]
Lang, JM [1 ]
机构：
[1] Hop Univ, CISIH Clin Med A, Strasbourg, France
来源：
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS | 2004年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [31] Safety and efficacy of ritonavir and saquinavir in combination with zidovudine and lamivudine
    Michelet, C
    Bellissant, E
    Ruffault, A
    Arvieux, C
    Delfraissy, JF
    Raffi, F
    Bazin, C
    Renard, I
    Sébille, V
    Chauvin, JP
    Dohin, E
    Cartier, F
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (06) : 661 - 671
  • [32] Predictors of genotypic resistance and virological response in antiretroviral naive HIV-1 infected patients treated with zidovudine plus didanosine.
    Vidal, C
    Pumarola, T
    Amedo, M
    Gil, C
    Garcia, F
    Zamora, L
    Cruceta, A
    Gatell, JM
    [J]. AIDS, 1998, 12 : S26 - S26
  • [33] Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients
    Jemsek, JG
    Arathoon, E
    Arlotti, M
    Perez, C
    Sosa, N
    Pokrovskiy, V
    Thiry, A
    Soccodato, M
    Noor, MA
    Giordano, M
    [J]. CLINICAL INFECTIOUS DISEASES, 2006, 42 (02) : 273 - 280
  • [34] THE SAFETY AND EFFICACY OF TENOFOVIR DF (TDF) IN COMBINATION WITH LAMIVUDINE (3TC) AND EFAVIRENZ (EFV) IN ANTIRETROVIRAL-NAIVE PATIENTS THROUGH SEVEN YEARS
    Carlevari, M.
    Cassetti, I.
    Madruga, J. V. R.
    Etzel, A.
    Suleiman, J.
    Zhou, Y.
    Cheng, A. K.
    Enejosa, J.
    [J]. INFECTION, 2009, 37 : 59 - 59
  • [35] The safety and efficacy of tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV) through 5 years in antiretroviral-naive patients
    Cassetti, I.
    Madruga, J. V. R.
    Suleiman, J. M. A. H.
    Zhong, L.
    Enejosa, J.
    Cheng, A. K.
    [J]. ANTIVIRAL THERAPY, 2006, 11 (07) : L50 - L51
  • [36] Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients
    Markowitz, M
    Hill-Zabala, C
    Lang, J
    DeJesus, E
    Liao, QM
    Lanier, ER
    Davis, EA
    Shaefer, M
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2005, 39 (03) : 257 - 264
  • [37] Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults
    DeJesus, E
    Herrera, G
    Teofilo, E
    Gerstoft, J
    Buendia, CB
    Brand, JD
    Brothers, CH
    Hernandez, J
    Castillo, SA
    Bonny, T
    Lanier, ER
    Scott, TR
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 39 (07) : 1038 - 1046
  • [38] Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1
    Benhamou, Y
    Thibault, V
    Vig, P
    Calvez, V
    Marcelin, AG
    Fievet, MN
    Currie, G
    Chang, CG
    Biao, L
    Xiong, S
    Brosgart, C
    Poynard, T
    [J]. JOURNAL OF HEPATOLOGY, 2006, 44 (01) : 62 - 67
  • [39] Safety and efficacy of rilpivirine-tenofovir-emtricitabine in treatment-experienced patients infected with HIV-1
    Cevik, M.
    Guy, L.
    Sonecha, S.
    Nelson, M.
    [J]. HIV MEDICINE, 2013, 14 : 58 - 58
  • [40] Antiretroviral activity and safety of abacavir in combination with selected HIV-1 protease inhibitors in therapy-naive HIV-1-infected adults
    McMahon, D
    Lederman, M
    Haas, DW
    Haubrich, R
    Stanford, J
    Cooney, E
    Horton, J
    Kelleher, D
    Ross, L
    Cutrell, A
    Lee, D
    Spreen, W
    Mellors, JW
    [J]. ANTIVIRAL THERAPY, 2001, 6 (02) : 105 - 114
12345